Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Beta Bionics, Inc.

NASDAQ: BBNX · Industrial Applications and Services · 9 alerts · CIK 1674632

Share price
$15.21Close, Nov 16
Market cap
$827M
Shares outstanding
54.37MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Beta Bionics, Inc. filings on SEC EDGAR ↗

4:01 PM ET Form 4
Insider Selling

Beta Bionics CFO Stephen Feider Sells $153K of Stock

Stephen Feider, CFO, sold 8,874 shares of Beta Bionics, Inc. at $17.21 a share, worth $153K in total on Nov 11, 2026. Shares held after the trade: 159,378 (-5.3%).

Value
$153K
Shares
8,874
Price
$17.21
Role
CFO
Holding change
-5.3%
Trade date
Nov 11, 2026
4:46 PM ET Form 4
Insider Selling

Beta Bionics CFO Stephen Feider Sells $12.6K of Stock

Stephen Feider, CFO, sold 744 shares of Beta Bionics, Inc. at $17.00 a share, worth $12.6K in total on Nov 9, 2026. Shares held after the trade: 159,378 (-0.5%).

Value
$12.6K
Shares
744
Price
$17.00
Role
CFO
Holding change
-0.5%
Trade date
Nov 9, 2026
4:22 PM ET Form 4
Insider Selling

Beta Bionics Chief Product Officer Mike Mensinger Sells $58.3K of Stock

Mike Mensinger, Chief Product Officer, sold 2,650 shares of Beta Bionics, Inc. at $22.00 a share, worth $58.3K in total on Oct 27, 2026. Shares held after the trade: 174,740 (-1.5%).

Value
$58.3K
Shares
2,650
Price
$22.00
Role
Chief Product Officer
Holding change
-1.5%
Trade date
Oct 27, 2026
4:03 PM ET Form 4
Insider Selling

Beta Bionics Chief Commercial Officer Mark Hopman Sells $16.4K of Stock

Mark Hopman, Chief Commercial Officer, sold 821 shares of Beta Bionics, Inc. at $20.00 a share, worth $16.4K in total on Oct 26, 2026. Shares held after the trade: 54,513 (-1.5%).

Value
$16.4K
Shares
821
Price
$20.00
Role
Chief Commercial Officer
Holding change
-1.5%
Trade date
Oct 26, 2026
4:21 PM ET 10-Q
Financial Results

Beta Bionics Q3 2026 Results: Net Loss of $24.4M, Loss Widens

Beta Bionics, Inc. reported net sales of $95.1 million for the nine months ended September 30, 2026, a significant increase from $68.1 million in the prior year period. Despite higher gross profits, the company's net loss widened to $69.7 million for the first nine months of 2026 due to increased operating expenses in sales, marketing, and R&D.

Key figure
Net loss $24.4M
4:04 PM ET 8-K
Financial Results

Beta Bionics Financial Results

Beta Bionics reported Q3 2026 net sales of $35.5 million, a 30% increase year-over-year, driven by significant growth in its Pharmacy Benefit Plan channel. The company updated its full-year 2026 revenue guidance to $124-$126 million and announced plans to resubmit its 510(k) for the 3D Intelligence algorithm in mid-Q4 2026.

4:11 PM ET Form 4
Insider Selling

Beta Bionics Chief Commercial Officer Mark Hopman Sells $13.4K of Stock

Mark Hopman, Chief Commercial Officer, sold 775 shares of Beta Bionics, Inc. at $17.35 a share, worth $13.4K in total on Oct 14, 2026. Shares held after the trade: 55,334 (-1.4%).

Value
$13.4K
Shares
775
Price
$17.35
Role
Chief Commercial Officer
Holding change
-1.4%
Trade date
Oct 14, 2026
6:01 AM ET 8-K
Capital Raise

Beta Bionics Capital Raise of $150M

Beta Bionics, Inc. priced a public offering of 7,652,175 shares of common stock and pre-funded warrants for gross proceeds of approximately $150.0 million. The offering was priced at $17.25 per share, and the company granted underwriters a 30-day option to purchase up to an additional 1,304,348 shares. Proceeds are intended for general corporate purposes, including the commercialization of its Mint product and manufacturing facility expansion.

Value
$150M
Counterparty
J.P. Morgan Securities LLC, Piper Sandler & Co., Wells Fargo Securities, LLC and Leerink Partners LLC
4:59 PM ET 8-K
Regulatory Approval

Beta Bionics Regulatory Approval

Beta Bionics received FDA clearance for Mint, its next-generation patch pump featuring a reusable and disposable architecture and smartphone control. The company also submitted a 510(k) application for its 3D Intelligence insulin dosing algorithm, which is expected to power its future automated insulin delivery platforms.

“We believe that our next-generation AID platform, consisting of Mint 3D and iLet 3D, will represent a transformational advancement for people living with diabetes, subject to regulatory clearance by the FDA.”

Sean Saint, President & CEO of Beta Bionics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.